Table of Contents
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of the earliest event reported): March 8, 2006
NEUROCRINE BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)
| Delaware (State or other jurisdiction of incorporation or organization) |
0-22705 (Commission File Number) |
33-0525145 (IRS Employer Identification No.) |
| 12790 El Camino Real | 92130 | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: (858) 617-7600
N/A
(Former name or former address, if changed since last report.)
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
| o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 | |
| o | CFR 240.14d-2 (b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 | |
| o | CFR 240.13e-4 (c)) |
TABLE OF CONTENTS
| Item 8.01 Other Events | ||||||||
| Item 9.01 Financial Statements and Exhibits | ||||||||
| SIGNATURES | ||||||||
| EXHIBIT 99.1 | ||||||||
Table of Contents
Item
8.01 Other Events
On March 8, 2006, Neurocrine Biosciences, Inc. issued a press release to provide an update on
the Company’s drug development pipeline, including the discontinuing of the development of the
APL-MS program. The full text of the press release issued in connection with the announcement is
filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
99.1 Press Release dated March 8, 2006
Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| Dated: March 13, 2006 | NEUROCRINE BIOSCIENCES, INC. |
|||
| /s/ PAUL W. HAWRAN | ||||
| Paul W. Hawran | ||||
| Executive Vice President and Chief Financial Officer |
||||
Exhibit 99.1
FOR IMMEDIATE RELEASE
Contact at Neurocrine Biosciences
Elizabeth Foster or ClaudiaWoodworth
(858) 617-7600
Contact at Neurocrine Biosciences
Elizabeth Foster or ClaudiaWoodworth
(858) 617-7600
NEUROCRINE BIOSCIENCES ANNOUNCES RESULTS OF THE PHASE II STUDY IN MULTIPLE SCLEROSIS
THE COMPANY ALSO PROVIDES UPDATE ON INDIPLON AND THE 2006 DEVELOPMENT PIPELINE
San Diego, CA, March 8, 2006 — Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced that
the results of its Phase II clinical trial using its altered peptide ligand (APL) technology for
Multiple Sclerosis (MS) did not meet its primary endpoint and demonstrate efficacy although the
product was safe and well tolerated. Based on these results, the Company has discontinued the
development of its APL-MS program. The Company will complete its other APL Phase II study, which
is evaluating the APL technology for the treatment of Type-1 diabetes, utilizing a different APL
epitope. Results of this trial are expected in the 3rd Quarter of 2006.
In other developments, the Company continues to anticipate that the proposed rule in the Federal
Register for the DEA to place indiplon into Schedule IV of the Controlled Substances Act (CSA) is
expected to occur shortly. This proposed action will be based on a recommendation from the Acting
Assistant Secretary for Health of the Department of Health and Human Services (DHHS) and on an
evaluation of the relevant data by DEA. Based on discussions with the DEA, the Company expects the
DEA will complete its process in parallel with the FDA review.
In addition, the Company reported on the progress of the other Clinical Development Goals for 2006.
Neurocrine is focusing on the advancement of several programs from early to mid-stage clinical
development for multiple therapeutic indications. The Company’s main clinical development
candidates include an oral, small-molecule GnRH antagonist for the treatment of endometriosis and
benign prostate hyperplasia, urocortin 2 for congestive heart failure (CHF), and a CRF antagonist
for anxiety/depression and irritable bowel syndrome (IBS). The Company is also advancing a back-up
compound for GnRH and has brought forward into clinical development a back-up CRF antagonist. In
addition, the Company has initiated a Phase I clinical trial for a new compound, an H1 antagonist,
NBI-75043, for the treatment of insomnia.
“Our Phase II study in multiple sclerosis patients showed APL-MS to have an excellent safety
profile, but unfortunately the study did not achieve statistical significance in efficacy in the
157 patients tested over the 9-month treatment period. Antigen specific recruitment of TH2 cells to
treat autoimmune disorders is a very appealing concept. We will continue to evaluate the clinical
benefits of the APL epitope to treat Type-1 diabetes, and will review this program based on Phase
II results expected mid-year. Neurocrine is continuing to focus its resources on several new
product candidates, which are currently advancing
through development, and we will report on these Phase II and proof of concept results throughout
this year,” said Wendell Wierenga, Ph.D, Executive Vice President of Research and Development for
Neurocrine Biosciences.
GnRH for Endometriosis Is On Track To Report Results in April 2006
Enrollment has been completed in the first three-month period of an ongoing Phase II study with NBI-56418 in 76 patients with endometriosis. The primary endpoint of the study is reduction in endometriotic pain as measured with the Composite Pelvic Sign and Symptoms Score (CPSSS), a validated clinical endpoint. Results from the 12-week, double-blind, placebo-controlled segment of the study are expected to be announced in early 2nd Quarter; the three-month safety follow-up period continues into the 2nd Quarter of 2006. A second Phase II study in patients with endometriosis was initiated in December 2005 to more fully explore dose response. This study, a multi-dose, double-blind placebo-controlled trial is enrolling 72 patients and is also designed to assess safety and efficacy over a three-month period with the primary endpoint of reduction in endometriotic pain as measured by CPSSS. Preliminary results are expected to be announced in the 3rd Quarter of 2006. In addition, the Company is preparing a third Phase II study, which will examine endometriosis in a six-month trial, which will measure efficacy and impact of treatment on bone mineral density. Finally the company recently started a Phase I study in male volunteers as part of the Benign Prostate Hyperplasia development program and expects to enter into Phase II studies late in 2006.
Enrollment has been completed in the first three-month period of an ongoing Phase II study with NBI-56418 in 76 patients with endometriosis. The primary endpoint of the study is reduction in endometriotic pain as measured with the Composite Pelvic Sign and Symptoms Score (CPSSS), a validated clinical endpoint. Results from the 12-week, double-blind, placebo-controlled segment of the study are expected to be announced in early 2nd Quarter; the three-month safety follow-up period continues into the 2nd Quarter of 2006. A second Phase II study in patients with endometriosis was initiated in December 2005 to more fully explore dose response. This study, a multi-dose, double-blind placebo-controlled trial is enrolling 72 patients and is also designed to assess safety and efficacy over a three-month period with the primary endpoint of reduction in endometriotic pain as measured by CPSSS. Preliminary results are expected to be announced in the 3rd Quarter of 2006. In addition, the Company is preparing a third Phase II study, which will examine endometriosis in a six-month trial, which will measure efficacy and impact of treatment on bone mineral density. Finally the company recently started a Phase I study in male volunteers as part of the Benign Prostate Hyperplasia development program and expects to enter into Phase II studies late in 2006.
Preliminary Positive Results With Urocortin 2 for Congestive Heart Failure
In November 2005, Neurocrine filed an IND application with the FDA to initiate a US Phase II study in stable CHF patients to further evaluate dose/response of urocortin 2 when administered over 4 hours. Initial results indicate that urocortin 2 is generally well tolerated and that the predicted hemodynamic effects on systolic and diastolic blood pressure, heart rate, cardiac work and, most importantly, cardiac output occur over the entire 4-hour infusion. Full study results are anticipated in the 3rd Quarter of 2006. This extended-infusion data will then provide guidance for dosing in the planned Phase IIb studies in the target population of patients with acute decompensated heart failure (ADHF). Results of this ADHF study are anticipated in the second half of 2007.
In November 2005, Neurocrine filed an IND application with the FDA to initiate a US Phase II study in stable CHF patients to further evaluate dose/response of urocortin 2 when administered over 4 hours. Initial results indicate that urocortin 2 is generally well tolerated and that the predicted hemodynamic effects on systolic and diastolic blood pressure, heart rate, cardiac work and, most importantly, cardiac output occur over the entire 4-hour infusion. Full study results are anticipated in the 3rd Quarter of 2006. This extended-infusion data will then provide guidance for dosing in the planned Phase IIb studies in the target population of patients with acute decompensated heart failure (ADHF). Results of this ADHF study are anticipated in the second half of 2007.
Corticotropin Releasing Factor (CRF) Antagonist Anticipated To Advance To Phase II Clinical Trials
In 2006
In collaboration with GlaxoSmithKline (GSK), the CRF program is progressing as planned through early stage clinical trials. Phase I trials are ongoing and GSK is planning to initiate Phase II trials in Anxiety/Depression during 2006.
In collaboration with GlaxoSmithKline (GSK), the CRF program is progressing as planned through early stage clinical trials. Phase I trials are ongoing and GSK is planning to initiate Phase II trials in Anxiety/Depression during 2006.
In addition to the Anxiety and Depression indication, GSK has an ongoing development program for
CRF1 receptor antagonists in Irritable Bowel Syndrome (IBS). GSK intends to advance the
lead CRF1 receptor antagonist compound into Phase II studies in irritable bowel syndrome
during 2006.
Irritable bowel syndrome is a gastrointestinal disease that affects approximately 30 million people
in the United States, accounting for over $25 billion in direct and indirect costs
each year, according to the International Foundation for Functional Gastrointestinal Disorders.
Although the exact pathophysiology of IBS is not well understood, there is increasing evidence to
suggest that underlying inflammation may influence the symptoms of pain and changes in bowel
pattern experienced by patients. Irritable bowel syndrome can be a lifelong, intermittent disease,
involving chronic or recurrent abdominal pain and frequent diarrhea or constipation.
Altered Peptide Ligand (APL) for Type 1 Diabetes
Neurocrine has completed enrollment in a Phase II, dose-response, safety, tolerability and efficacy trial in approximately 188 adults/adolescents with new onset Type-1 diabetes. Results from this study are expected in the 3rd Quarter of 2006.
Neurocrine has completed enrollment in a Phase II, dose-response, safety, tolerability and efficacy trial in approximately 188 adults/adolescents with new onset Type-1 diabetes. Results from this study are expected in the 3rd Quarter of 2006.
Additional Compound for Insomnia Enters Clinical Development
Neurocrine initiated a Phase I study in the 1st Quarter of 2006 of a new compound, NBI-75043, for the treatment of insomnia. NBI-75043 is an orally-active, highly-selective and short-acting agent. The Phase I studies which will evaluate the safety and PK of single and multiple doses as well as selected sleep-related parameters will be completed in the second half of 2006, at which time the company anticipates to initiate early Phase II proof of concept studies.
Neurocrine initiated a Phase I study in the 1st Quarter of 2006 of a new compound, NBI-75043, for the treatment of insomnia. NBI-75043 is an orally-active, highly-selective and short-acting agent. The Phase I studies which will evaluate the safety and PK of single and multiple doses as well as selected sleep-related parameters will be completed in the second half of 2006, at which time the company anticipates to initiate early Phase II proof of concept studies.
Additional Research Programs
Neurocrine’s Research Group continues to advance novel small molecule compounds into clinical development. Neurocrine scientists are focusing on developing small molecule antagonists against G-protein coupled receptors. In addition, Neurocrine scientists are also currently reviewing in preclinical studies A2A antagonists for the treatment of Parkinson’s disease.
Neurocrine’s Research Group continues to advance novel small molecule compounds into clinical development. Neurocrine scientists are focusing on developing small molecule antagonists against G-protein coupled receptors. In addition, Neurocrine scientists are also currently reviewing in preclinical studies A2A antagonists for the treatment of Parkinson’s disease.
Neurocrine Biosciences, Inc. is a product-based biopharmaceutical Company focused on neurological
and endocrine diseases and disorders. Our product candidates address some of the largest
pharmaceutical markets in the world including insomnia, anxiety, depression, diabetes, irritable
bowel syndrome, and autoimmunity. Neurocrine Biosciences, Inc. news releases are available through
the Company’s website via the Internet at http://www.neurocrine.com
In addition to historical facts, this press release may contain forward-looking statements that
involve a number of risks and uncertainties. Among the factors that could cause actual results to
differ materially from those indicated in the forward looking statements are risks and
uncertainties associated with Neurocrine’s business and finances and research programs in general
including, but not limited to, risk and uncertainties associated with the Company’s indiplon
program and research and development activities. Specifically, the risks and uncertainties the
Company faces with respect to its indiplon program include, but are not limited to risk that
regulatory authorities may find either or both of our indiplon NDAs incomplete or insufficient or
for any other reason not approvable; risk associated with our reliance on our strategic alliance
partner for manufacturing and commercialization of indiplon; risk that following approval of
indiplon commercialization may be delayed for any of a number of reasons including market
conditions and product supply; risk that the indiplon labeling granted by regulatory
authorities may limit the commercial success of indiplon; and risk relating to market acceptance
of indiplon following marketing approval. Specifically, the risks and uncertainties the Company
faces with respect to the Company’s drug discovery, pre-clinical and clinical development of
products including, risk that the GnRH receptor antagonist, urocortin 2, CRF antagonist, Type-1
diabetes altered peptide ligand, and H1 antagonist clinical candidates will not proceed to later
stage clinical trials; risk that in later stage clinical trials the Company’s clinical candidates
will fail to demonstrate that they are safe and/or efficacious in treating the targeted disease
states; risk relating to the Company’s dependence on contract manufacturers for clinical drug
supply and compliance with regulatory requirements for marketing approval; risks associated with
the Company’s dependence on third parties for commercial manufacturing activities; uncertainties
relating to patent protection and intellectual property rights of third parties; risks and
uncertainties relating to competitive products and technological changes that may limit demand for
the Company’s products; risk that the Company will be unable to raise additional funding required
to complete development of all of its product candidates; and the other risks described in the
Company’s report on Form 10-K for the year ended December 31, 2005. Neurocrine undertakes no
obligation to update the statements contained in this press release after the date hereof.
# # #